Differential approach in selecting beta-adrenoblocker therapy for patients with chronic heart failure and anaemia
https://doi.org/10.15829/1728-8800-2012-2-62-69
Abstract
Currently, beta-adrenoblockers (β-AB) are regarded as one of the major medication classes in the treatment of patients with chronic heart failure (CHF). In several international studies, β -AB therapy of CHF patients was associated with reduced levels of haemoglobin (Hb) and development of new anaemia cases. Anaemia is known as an adverse prognostic factor in CHF.
Aim. To study the effects of β -AB therapy on the anaemia clinical course among CHF patients.
Material and methods. The study included 90 ambulatory patients with Functional Class (FC) II-IV CHF and anaemia. The participants were divided into 3 equally sized groups (n=30 per group) and treated with carvedilol, metoprolol, or nebivolol for 6 months.
Results. By the end of the follow-up, baseline Hb levels increased in the nebivolol group (p=0,028), and were also significantly higher than in the other two groups. In the carvedilol group, the levels of haematocrit (Ht) and glomerular filtration rate (GFR) significantly decreased (p=0,017 and 0,06, respectively). In the metoprolol group, no substantial changes of laboratory parameters were observed. The maximal reduction in baseline CHF FC was registered in the patients receiving nebivolol (p=0,037). A significant improvement in myocardial contractility, based on the echocardiography data, was registered in the carvedilol and nebivolol groups.
Conclusion. Nebivolol therapy was associated with a significantly more pronounced reduction in pro-BNP levels, compared to carvedilol or metoprolol treatment (p<0,001). The nebivolol group also demonstrated the most pronounced improvement in quality of life of CHF patients (p<0,001). These findings suggest that nebivolol could be recommended as a medication of choice in patients with CHF and anaemia.
About the Authors
T. M. Uskach
GBOU VPO «Moscow State University of Medicine and Dentistry», 20/1 Delegatskaya str., 127473, Moscow
Russian Federation
Russian Federation
A. G. Kochetov
Reseach Center of cerebrovasculare pathology and stroke of GOU VPO «Russian State Medical University» of Roszdrav, ul. Ostrovityanova, 1, 117997 Moscow
Russian Federation
Russian Federation
S. N. Tereschenko
Russian Cardiology Scientific and Production Center, ul. Tretya Cherepkovskaya 15a, 121552 Moscow
Russian Federation
Russian Federation
References
1. Kasatova TB, Shipilov AV Place of beta-blockers in treatment of chronic heart failure. Russian Medical Journal 2008; 4: 227-9. Russian (Касатова Т.Б., Шипилов А.В. Место бета-блокаторов в лечении хронической сердечной недостаточности. РМЖ 2008; 4: 227-9).
2. National guidelines for the diagnosis and treatment of chronic heart failure (the third revision). Heart Failure 2010; 11(1): 69-160. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (третий пересмотр). Серд недост 2010; 11(1): 69-160).
3. Preobrazhenskij DV, Sidorenko BA, Pataraja SA, et al. Nebivolol – b-blocker the third generation in treatment of cardiovascular diseases. Russian Medical Journal 2008; 16(5): 277-84. Russian (Преображенский Д.В., Сидоренко Б.А., Патарая С.А. и др. Небиволол – b-адреноблокатор третьего поколения в лечении сердечно–сосудистых заболеваний. Российский кардиологический журнал 2008; 16(5): 277-84).
4. Orlov VA, Giljarevskij SR, Urusbieva DM et al. Influence of side-effects angiotensin-converting enzyme inhibitors enzymes on tactics of treat-ment of cardiovascular diseases. Russ J Cardiol 2005; 3: 45-9. Russian (Орлов В.А., Гиляревский С.Р., Урусбиева Д.М. и др. Влияние побочных эффектов на тактику лечения сердечно–сосудистых заболеваний. Российский кардиологический журнал 2005; 3: 45-9).
5. Komajda M, Anker SD, Charlesworth A. et al. for the COMET Investigators. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006; 27(12) :1440-6.
6. Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007; 28(1): 166-71.
7. Feldman S, Rachmilewitz A, Izak G, The effect of central nervous system stimulation on erythropoiesis in rats with chronically implanted electrodes. J Lab Clin Medl 1966; 67: 713-25.
8. Lefkowitz R, Gimbird L, Mukhergee C, Caron M The beta-adrenergic receptor and adenylate cyclase. Biohim Biophys Acta 1976; 457: 1-39.
9. Mladenovic J, Adamson JW Adrenergic modulation of erythropoiesis: in vitro studies of colony – forming cells in normal and polycythaemic man. Br J Haematol 1984; 56: 323-32.
10. Przala F, Gross DM, Beckman B, Fisher JW Influence of albuterol on erythropoietin production and erythroid progenitor cell activation. Am J Physiol 1979; 236: H422-6.
11. Gattis WA Metoprolol CR/XL in the treatment of chronic heart failure. Pharmacotherapy 2001; 21(5): 604-13.
12. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342(8885): 1441-6.
Review
For citations:
Uskach T.M., Kochetov A.G., Tereschenko S.N. Differential approach in selecting beta-adrenoblocker therapy for patients with chronic heart failure and anaemia. Cardiovascular Therapy and Prevention. 2012;11(2):62-69. (In Russ.) https://doi.org/10.15829/1728-8800-2012-2-62-69
Views:
715
Email this article 
